Free Trial
OTCMKTS:BTCY

Biotricity Q1 2025 Earnings Report

Biotricity logo
$0.67 -0.01 (-1.53%)
As of 01:52 PM Eastern

Biotricity EPS Results

Actual EPS
-$0.49
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Biotricity Revenue Results

Actual Revenue
$3.20 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biotricity Announcement Details

Quarter
Q1 2025
Time
N/A
Conference Call Date
Wednesday, August 21, 2024
Conference Call Time
2:00AM ET

Biotricity Earnings Headlines

Prepare for the “Mar-a-Lago Accord” Money Shock
Why Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for your money than tariffs is unfolding behind the scenes... Tucked inside this overlooked directive is a plan set to be executed for the first time in in U.S. history. One Stansberry Research's Senior Partner says it's set to trigger a rare window for potentially explosive gains in ONE asset immediately. (Not AI or crypto). Wall Street insiders are already positioning themselves... and he insists you should, too, before it's too late.tc pixel
Rogue Funds’ New Holding: Biotricity (BTCY)
See More Biotricity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biotricity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biotricity and other key companies, straight to your email.

About Biotricity

Biotricity (OTCMKTS:BTCY) (OTCMKTS:BTCY) is a medical device and digital health company specializing in remote cardiovascular monitoring and chronic disease management. The company’s flagship offering, the Bioflux system, integrates a wearable ECG patch with a cloud-based analytics platform to deliver real-time heart rhythm data and diagnostic insights. By combining wireless biosensors, mobile applications, and secure data transmission, Biotricity aims to simplify patient monitoring for healthcare providers and enhance early detection of arrhythmias and other cardiac events.

In addition to its core ambulatory ECG solution, Biotricity provides a suite of digital health products designed for broader chronic care management. These include a patient-facing mobile app for symptom tracking and medication reminders, as well as a clinician portal that aggregates and visualizes patient data. The company’s technology is engineered to meet regulatory requirements in multiple markets, including FDA clearance in the United States and CE Mark approval in Europe, positioning Biotricity to serve healthcare systems, telehealth providers, and home health agencies worldwide.

Founded in 2011 and headquartered in the San Francisco Bay Area, Biotricity leverages a multidisciplinary leadership team drawn from the medical device, software development, and clinical research sectors. Under the guidance of founder and CEO Kenneth Tam, the company has grown its operational footprint across North America and Europe, forging partnerships with cardiology practices and remote monitoring service providers. Biotricity continues to focus on innovative sensor technology and data analytics to drive improved patient outcomes and reduce the burden on healthcare facilities.

View Biotricity Profile

More Earnings Resources from MarketBeat